当前位置: 首页 >> 检索结果
101. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
作者: Timothy L Jackson.;Riti Desai.;Hatem A Wafa.;Yanzhong Wang.;Janet Peacock.;Tunde Peto.;Usha Chakravarthy.;Helen Dakin.;Sarah Wordsworth.;Cornelius Lewis.;Patricia Clinch.;Lisa Ramazzotto.;James E Neffendorf.;Chan Ning Lee.;Joe M O'Sullivan.;Barnaby C Reeves.; .
来源: Lancet. 2024年404卷10447期44-54页
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of anti-VEGF injections required, without sacrificing visual acuity.
102. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
作者: Peter Kelly.;Robin Lemmens.;Christian Weimar.;Cathal Walsh.;Francisco Purroy.;Mark Barber.;Ronan Collins.;Simon Cronin.;Anna Czlonkowska.;Philippe Desfontaines.;Adinda De Pauw.;Nicholas Richard Evans.;Urs Fischer.;Catarina Fonseca.;John Forbes.;Michael D Hill.;Dalius Jatuzis.;Janika Kõrv.;Peter Kraft.;Christina Kruuse.;Catherine Lynch.;Dominick McCabe.;Robert Mikulik.;Sean Murphy.;Paul Nederkoorn.;Martin O'Donnell.;Peter Sandercock.;Bernadette Schroeder.;Gek Shim.;Katrina Tobin.;David J Williams.;Christopher Price.
来源: Lancet. 2024年404卷10448期125-133页
Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.
103. Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial.
作者: Rahul Raj.;Pihla Tommiska.;Timo Koivisto.;Ville Leinonen.;Nils Danner.;Jussi P Posti.;Dan Laukka.;Teemu Luoto.;Minna Rauhala.;Sami Tetri.;Tommi K Korhonen.;Jarno Satopää.;Riku Kivisaari.;Teemu Luostarinen.;Christoph Schwartz.;Tomasz Czuba.;Simo Taimela.;Kimmo Lönnrot.;Teppo L N Järvinen.; .
来源: Lancet. 2024年403卷10446期2798-2806页
Chronic subdural haematoma is a common surgically treated intracranial emergency. Burr-hole drainage surgery, to evacuate chronic subdural haematoma, involves three elements: creation of a burr hole for access, irrigation of the subdural space, and insertion of a subdural drain. Although the subdural drain has been established as beneficial, the therapeutic effect of subdural irrigation has not been addressed.
104. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
作者: Simron Singh.;Daniel Halperin.;Sten Myrehaug.;Ken Herrmann.;Marianne Pavel.;Pamela L Kunz.;Beth Chasen.;Salvatore Tafuto.;Secondo Lastoria.;Jaume Capdevila.;Amparo García-Burillo.;Do-Youn Oh.;Changhoon Yoo.;Thorvardur R Halfdanarson.;Stephen Falk.;Ilya Folitar.;Yufen Zhang.;Paola Aimone.;Wouter W de Herder.;Diego Ferone.; .
来源: Lancet. 2024年403卷10446期2807-2817页
There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment.
105. Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial.
作者: Christopher Patrick Bretherton.;Juul Achten.;Vidoushee Jogarah.;Stavros Petrou.;Nicholas Peckham.;Felix Achana.;Duncan Appelbe.;Rebecca Kearney.;Harry Claireux.;Philip Bell.;Xavier L Griffin.; .
来源: Lancet. 2024年403卷10446期2787-2797页
After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy.
106. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Hans Gelderblom.;Vivek Bhadri.;Silvia Stacchiotti.;Sebastian Bauer.;Andrew J Wagner.;Michiel van de Sande.;Nicholas M Bernthal.;Antonio López Pousa.;Albiruni Abdul Razak.;Antoine Italiano.;Mahbubl Ahmed.;Axel Le Cesne.;Gabriel Tinoco.;Kjetil Boye.;Javier Martín-Broto.;Emanuela Palmerini.;Salvatore Tafuto.;Sarah Pratap.;Benjamin C Powers.;Peter Reichardt.;Antonio Casado Herráez.;Piotr Rutkowski.;Christopher Tait.;Fiona Zarins.;Brooke Harrow.;Maitreyi G Sharma.;Rodrigo Ruiz-Soto.;Matthew L Sherman.;Jean-Yves Blay.;William D Tap.; .
来源: Lancet. 2024年403卷10445期2709-2719页
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery.
107. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
作者: Xu Liu.;Yuan Zhang.;Kun-Yu Yang.;Ning Zhang.;Feng Jin.;Guo-Rong Zou.;Xiao-Dong Zhu.;Fang-Yun Xie.;Xiao-Yu Liang.;Wen-Fei Li.;Zhen-Yu He.;Nian-Yong Chen.;Wei-Han Hu.;Hai-Jun Wu.;Mei Shi.;Guan-Qun Zhou.;Yan-Ping Mao.;Rui Guo.;Rui Sun.;Jing Huang.;Shao-Qiang Liang.;Wei-Li Wu.;Zhen Su.;Ling Li.;Ping Ai.;Yu-Xiang He.;Jian Zang.;Lei Chen.;Li Lin.;Shao Hui Huang.;Cheng Xu.;Jia-Wei Lv.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Sai-Wei Huang.;Ye-Lin Liang.;Ya-Qin Wang.;Ying-Lin Peng.;Jin-Han Zhu.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ai-Hua Lin.;Ji-Bin Li.;Na Liu.;Ling-Long Tang.;Yu-Pei Chen.;Ying Sun.;Jun Ma.
来源: Lancet. 2024年403卷10445期2720-2731页
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population.
108. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.
作者: Andreas Baumbach.;Niels van Royen.;Ignacio J Amat-Santos.;Martin Hudec.;Matjaz Bunc.;Alexander Ijsselmuiden.;Peep Laanmets.;Daniel Unic.;Bela Merkely.;Renicus S Hermanides.;Vlasis Ninios.;Marcin Protasiewicz.;Benno J W M Rensing.;Pedro L Martin.;Fausto Feres.;Manuel De Sousa Almeida.;Eric van Belle.;Axel Linke.;Alfonso Ielasi.;Matteo Montorfano.;Mark Webster.;Konstantinos Toutouzas.;Emmanuel Teiger.;Francesco Bedogni.;Michiel Voskuil.;Manuel Pan.;Oskar Angerås.;Won-Keun Kim.;Jürgen Rothe.;Ivica Kristić.;Vicente Peral.;Scot Garg.;Hesham Elzomor.;Akihiro Tobe.;Marie-Claude Morice.;Yoshinobu Onuma.;Osama Soliman.;Patrick W Serruys.; .
来源: Lancet. 2024年403卷10445期2695-2708页
Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA).
109. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
作者: Alexa B Kimball.;Gregor B E Jemec.;Christopher J Sayed.;Joslyn S Kirby.;Errol Prens.;John R Ingram.;Amit Garg.;Alice B Gottlieb.;Jacek C Szepietowski.;Falk G Bechara.;Evangelos J Giamarellos-Bourboulis.;Hideki Fujita.;Robert Rolleri.;Paulatsya Joshi.;Pratiksha Dokhe.;Edward Muller.;Luke Peterson.;Cynthia Madden.;Muhammad Bari.;Christos C Zouboulis.
来源: Lancet. 2024年403卷10443期2504-2519页
Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa.
110. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
作者: Suhaniya N S Samarasinghe.;Bianca Leca.;Shahd Alabdulkader.;Georgios K Dimitriadis.;Allan Davasgaium.;Puja Thadani.;Kate Parry.;Migena Luli.;Karen O'Donnell.;Brett Johnson.;Ali Abbara.;Florian Seyfried.;Rachel Morman.;Ahmed R Ahmed.;Sherif Hakky.;Christos Tsironis.;Sanjay Purkayastha.;Carel W le Roux.;Stephen Franks.;Vinod Menon.;Harpal Randeva.;Alexander D Miras.
来源: Lancet. 2024年403卷10443期2489-2503页
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Obesity exacerbates the reproductive complications of PCOS; however, the management of obesity in women with PCOS remains a large unmet clinical need. Observational studies have indicated that bariatric surgery could improve the rates of ovulatory cycles and prospects of fertility; however, the efficacy of surgery on ovulation rates has not yet been compared with behavioural modifications and medical therapy in a randomised trial. The aim of this study was to compare the safety and efficacy of bariatric surgery versus medical care on ovulation rates in women with PCOS, obesity, and oligomenorrhoea or amenorrhoea.
111. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
作者: Amanda I Adler.;Ruth L Coleman.;Jose Leal.;William N Whiteley.;Philip Clarke.;Rury R Holman.
来源: Lancet. 2024年404卷10448期145-155页
The 20-year UK Prospective Diabetes Study showed major clinical benefits for people with newly diagnosed type 2 diabetes randomly allocated to intensive glycaemic control with sulfonylurea or insulin therapy or metformin therapy, compared with conventional glycaemic control. 10-year post-trial follow-up identified enduring and emerging glycaemic and metformin legacy treatment effects. We aimed to determine whether these effects would wane by extending follow-up for another 14 years.
112. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
作者: Shelagh B Coutts.;Sandeep Ankolekar.;Ramana Appireddy.;Juan F Arenillas.;Zarina Assis.;Peter Bailey.;Philip A Barber.;Rodrigo Bazan.;Brian H Buck.;Ken S Butcher.;Marie-Christine Camden.;Bruce C V Campbell.;Leanne K Casaubon.;Luciana Catanese.;Kausik Chatterjee.;Philip M C Choi.;Brian Clarke.;Dar Dowlatshahi.;Julia Ferrari.;Thalia S Field.;Aravind Ganesh.;Darshan Ghia.;Mayank Goyal.;Stefan Greisenegger.;Omid Halse.;Mackenzie Horn.;Gary Hunter.;Oje Imoukhuede.;Peter J Kelly.;James Kennedy.;Carol Kenney.;Timothy J Kleinig.;Kailash Krishnan.;Fabricio Lima.;Jennifer L Mandzia.;Martha Marko.;Sheila O Martins.;George Medvedev.;Bijoy K Menon.;Sachin M Mishra.;Carlos Molina.;Aimen Moussaddy.;Keith W Muir.;Mark W Parsons.;Andrew M W Penn.;Arthur Pille.;Octávio M Pontes-Neto.;Christine Roffe.;Joaquin Serena.;Robert Simister.;Nishita Singh.;Neil Spratt.;Daniel Strbian.;Carol H Tham.;M Ivan Wiggam.;David J Williams.;Mark R Willmot.;Teddy Wu.;Amy Y X Yu.;George Zachariah.;Atif Zafar.;Charlotte Zerna.;Michael D Hill.; .
来源: Lancet. 2024年403卷10444期2597-2605页
Individuals with minor ischaemic stroke and intracranial occlusion are at increased risk of poor outcomes. Intravenous thrombolysis with tenecteplase might improve outcomes in this population. We aimed to test the superiority of intravenous tenecteplase over non-thrombolytic standard of care in patients with minor ischaemic stroke and intracranial occlusion or focal perfusion abnormality.
113. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
作者: Chris C Parker.;Noel W Clarke.;Adrian D Cook.;Howard Kynaston.;Charles N Catton.;William R Cross.;Peter M Petersen.;Rajendra A Persad.;Fred Saad.;Lorna C Bower.;John Logue.;Heather Payne.;Silvia Forcat.;Cindy Goldstein.;Claire Murphy.;Juliette Anderson.;Maroie Barkati.;David M Bottomley.;Jennifer Branagan.;Ananya Choudhury.;Peter W M Chung.;Lyn Cogley.;Chee L Goh.;Peter Hoskin.;Vincent Khoo.;Shawn C Malone.;Lindsey Masters.;Stephen L Morris.;Abdenour Nabid.;Aldrich D Ong.;Rakesh Raman.;Kathryn L Tarver.;Alison C Tree.;Jane Worlding.;James P Wylie.;Anjali M Zarkar.;Wendy R Parulekar.;Mahesh K B Parmar.;Matthew R Sydes.; .
来源: Lancet. 2024年403卷10442期2405-2415页
Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear.
114. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
作者: Chris C Parker.;Howard Kynaston.;Adrian D Cook.;Noel W Clarke.;Charles N Catton.;William R Cross.;Peter M Petersen.;Rajendra A Persad.;Cheryl A Pugh.;Fred Saad.;John Logue.;Heather Payne.;Lorna C Bower.;Chris Brawley.;Mary Rauchenberger.;Maroie Barkati.;David M Bottomley.;Klaus Brasso.;Hans T Chung.;Peter W M Chung.;Ruth Conroy.;Alison Falconer.;Vicky Ford.;Chee L Goh.;Catherine M Heath.;Nicholas D James.;Charmaine Kim-Sing.;Ravi Kodavatiganti.;Shawn C Malone.;Stephen L Morris.;Abdenour Nabid.;Aldrich D Ong.;Rakesh Raman.;Sree Rodda.;Paula Wells.;Jane Worlding.;Wendy R Parulekar.;Mahesh K B Parmar.;Matthew R Sydes.; .
来源: Lancet. 2024年403卷10442期2416-2425页
Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain.
115. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial.
作者: Jürgen Beck.;Christian Fung.;Daniel Strbian.;Lukas Bütikofer.;Werner J Z'Graggen.;Matthias F Lang.;Seraina Beyeler.;Jan Gralla.;Florian Ringel.;Karl Schaller.;Nikolaus Plesnila.;Marcel Arnold.;Werner Hacke.;Peter Jüni.;Alexander David Mendelow.;Christian Stapf.;Rustam Al-Shahi Salman.;Jenny Bressan.;Stefanie Lerch.;Arsany Hakim.;Nicolas Martinez-Majander.;Anna Piippo-Karjalainen.;Peter Vajkoczy.;Stefan Wolf.;Gerrit A Schubert.;Anke Höllig.;Michael Veldeman.;Roland Roelz.;Andreas Gruber.;Philip Rauch.;Dorothee Mielke.;Veit Rohde.;Thomas Kerz.;Eberhard Uhl.;Enea Thanasi.;Hagen B Huttner.;Bernd Kallmünzer.;L Jaap Kappelle.;Wolfgang Deinsberger.;Christian Roth.;Robin Lemmens.;Jan Leppert.;Jose L Sanmillan.;Jonathan M Coutinho.;Katharina A M Hackenberg.;Gernot Reimann.;Mikael Mazighi.;Claudio L A Bassetti.;Heinrich P Mattle.;Andreas Raabe.;Urs Fischer.; .
来源: Lancet. 2024年403卷10442期2395-2404页
It is unknown whether decompressive craniectomy improves clinical outcome for people with spontaneous severe deep intracerebral haemorrhage. The SWITCH trial aimed to assess whether decompressive craniectomy plus best medical treatment in these patients improves outcome at 6 months compared to best medical treatment alone.
116. Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation.
作者: Victor Tumukunde.;Melissa M Medvedev.;Cally J Tann.;Ivan Mambule.;Catherine Pitt.;Charles Opondo.;Ayoub Kakande.;Ruth Canter.;Yiga Haroon.;Charity Kirabo-Nagemi.;Andrew Abaasa.;Wilson Okot.;Fredrick Katongole.;Raymond Ssenyonga.;Natalia Niombi.;Carol Nanyunja.;Diana Elbourne.;Giulia Greco.;Elizabeth Ekirapa-Kiracho.;Moffat Nyirenda.;Elizabeth Allen.;Peter Waiswa.;Joy E Lawn.; .
来源: Lancet. 2024年403卷10443期2520-2532页
Preterm birth is the leading cause of death in children younger than 5 years worldwide. WHO recommends kangaroo mother care (KMC); however, its effects on mortality in sub-Saharan Africa and its relative costs remain unclear. We aimed to compare the effectiveness, safety, costs, and cost-effectiveness of KMC initiated before clinical stabilisation versus standard care in neonates weighing up to 2000 g.
117. Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.
作者: Rebecca L Gould.;Christopher J McDermott.;Benjamin J Thompson.;Charlotte V Rawlinson.;Matt Bursnall.;Mike Bradburn.;Pavithra Kumar.;Emily J Turton.;David A White.;Marc A Serfaty.;Christopher D Graham.;Lance M McCracken.;Laura H Goldstein.;Ammar Al-Chalabi.;Richard W Orrell.;Tim Williams.;Rupert Noad.;Idris Baker.;Christina Faull.;Thomas Lambert.;Suresh K Chhetri.;John Ealing.;Anthony Hanratty.;Aleksandar Radunovic.;Nushan Gunawardana.;Gail Meadows.;George H Gorrie.;Tracey Young.;Vanessa Lawrence.;Cindy Cooper.;Pamela J Shaw.;Robert J Howard.; .
来源: Lancet. 2024年403卷10442期2381-2394页
Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease.
118. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
作者: Martin Dreyling.;Jeanette Doorduijn.;Eva Giné.;Mats Jerkeman.;Jan Walewski.;Martin Hutchings.;Ulrich Mey.;Jon Riise.;Marek Trneny.;Vibeke Vergote.;Ofer Shpilberg.;Maria Gomes da Silva.;Sirpa Leppä.;Linmiao Jiang.;Stephan Stilgenbauer.;Andrea Kerkhoff.;Ron D Jachimowicz.;Melania Celli.;Georg Hess.;Luca Arcaini.;Carlo Visco.;Tom van Meerten.;Stefan Wirths.;Pier Luigi Zinzani.;Urban Novak.;Peter Herhaus.;Fabio Benedetti.;Kristina Sonnevi.;Christine Hanoun.;Matthias Hänel.;Judith Dierlamm.;Christiane Pott.;Wolfram Klapper.;Döndü Gözel.;Christian Schmidt.;Michael Unterhalt.;Marco Ladetto.;Eva Hoster.
来源: Lancet. 2024年403卷10441期2293-2306页
Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT.
119. Extended optical treatment versus early patching with an intensive patching regimen in children with amblyopia in Europe (EuPatch): a multicentre, randomised controlled trial.
作者: Frank A Proudlock.;Michael Hisaund.;Gail Maconachie.;Eleni Papageorgiou.;Ali Manouchehrinia.;Annegret Dahlmann-Noor.;Payal Khandelwal.;Jay Self.;Christina Beisse.;Irene Gottlob.; .
来源: Lancet. 2024年403卷10438期1766-1778页
Amblyopia, the most common visual impairment of childhood, is a public health concern. An extended period of optical treatment before patching is recommended by the clinical guidelines of several countries. The aim of this study was to compare an intensive patching regimen, with and without extended optical treatment (EOT), in a randomised controlled trial.
120. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
作者: Ikechukwu Adigweme.;Mohammed Yisa.;Michael Ooko.;Edem Akpalu.;Andrew Bruce.;Simon Donkor.;Lamin B Jarju.;Baba Danso.;Anthony Mendy.;David Jeffries.;Anne Segonds-Pichon.;Abdoulie Njie.;Stephen Crooke.;Elina El-Badry.;Hilary Johnstone.;Michael Royals.;James L Goodson.;Mark R Prausnitz.;Devin V McAllister.;Paul A Rota.;Sebastien Henry.;Ed Clarke.
来源: Lancet. 2024年403卷10439期1879-1892页
Microneedle patches (MNPs) have been ranked as the highest global priority innovation for overcoming immunisation barriers in low-income and middle-income countries. This trial aimed to provide the first data on the tolerability, safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children.
|